Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs ResMed Inc. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while ResMed Inc. trades at $236.34 (market cap $33.09B). The key difference: ResMed Inc. is far larger — about 3.7× Kymera Therapeutics Inc. Common Stock's market cap, and ResMed Inc. pays a 1.12% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and ResMed Inc. for 51 Days on average.
| KYMR | RMD | |
|---|---|---|
Market Cap | $8.88B | $33.09B |
Volume | 1,028,790 | 1,019,685 |
Sector | Health | Health |
52-Week High | $127.31 | $275.96 |
52-Week Low | $55.80 | $182.82 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $8.27B | $32.45B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ResMed (RMD) trades at $235.04, up 0.19% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $243.56. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding expectations. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%, while cash flow from operations reached $1.75B. Recent news highlights upcoming Q1 2027 earnings and a Morgan Stanley conference presentation focusing on growth targets.
The outlook for RMD is positive, driven by consistent earnings outperformance, high profitability, and institutional buying interest. Key opportunities include market share gains and product innovation in sleep therapy, though risks involve competitive pressures and ongoing legal investigations. The stock's current valuation metrics, including a P/E of 22.56, appear reasonable relative to growth, supporting a constructive view for investors seeking exposure to healthcare equipment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
